Browse

Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

1 claim

The IL-1β-blocking monoclonal antibody canakinumab: its cardiovascular outcomes evidence (notably the CANTOS trial), effects on inflammatory biomarkers such as CRP, safety (e.g., infection risk), and use in patients with residual inflammatory risk. Not for other anti-inflammatory agents unless directly compared.

In the CANTOS trial, canakinumab reduced recurrent cardiovascular events without lowering LDL cholesterol

VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Inflammation in atherosclerosis Atherosclerotic cardiovascular disease LDL cholesterolimportance · minorImportance 0.35, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim entirely, propose it below. A proposal is reviewed on its merits; accepted claims are matched against the graph and enter it with their reasoning on record.